SGLT2 Inhibitor Use Tied to Fewer Atrial Arrhythmias SGLT2 Inhibitor Use Tied to Fewer Atrial Arrhythmias
Patients with cardiac implantable electronic devices who were treated with an SGLT2 inhibitor had significantly fewer atrial arrhythmias vs those never receiving them, new observational data suggest.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - December 2, 2021 Category: Primary Care Tags: Cardiology News Source Type: news

Algorithm Predicts Response to SGLT2, DPP-4 Inhibitors in Diabetes Algorithm Predicts Response to SGLT2, DPP-4 Inhibitors in Diabetes
British investigators derived and validated an algorithm, available online, for predicting response of patients with type 2 diabetes to agents from two different classes of glucose-lowering drugs.First Look (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - November 29, 2021 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news

At What Price Will Newer Anti-Diabetes Drugs Be Cost Effective? At What Price Will Newer Anti-Diabetes Drugs Be Cost Effective?
In low- to middle-income countries, SGLT2 inhibitors could reduce diabetes complications at lower but feasible prices; they are cost effective at current prices in people with heart or kidney disease.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 24, 2021 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Canagliflozin Improves HF Symptoms in Fully Remote Trial Canagliflozin Improves HF Symptoms in Fully Remote Trial
The benefit of the SGLT2 inhibitor was consistent, regardless of ejection fraction and presence or absence of type 2 diabetes, in the decentralized CHIEF-HF trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 17, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Empagliflozin Wins in Tough Stabilized Acute-HF Setting Empagliflozin Wins in Tough Stabilized Acute-HF Setting
Early in-hospital initiation of SGLT2 inhibitors'should be considered the new standard of care'in most patients with heart failure regardless of their ejection fraction, says an expert observer.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 16, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Which Patients With Type 2 Diabetes Need SGLT2 Inhibitors? Which Patients With Type 2 Diabetes Need SGLT2 Inhibitors?
With an essential role established for SGLT2 inhibitors for patients with progressive renal dysfunction or heart failure, researchers discuss how best to use these agents in those with type 2 diabetes.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - October 28, 2021 Category: Primary Care Tags: Diabetes & Endocrinology News Source Type: news

Which Patients With Type 2 Diabetes Need SGLT2
Inhibitors? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 28, 2021 Category: General Medicine Source Type: news

SGLT2 Inhibitors for Diabetes: No Link to Fractures in Older Adults SGLT2 Inhibitors for Diabetes: No Link to Fractures in Older Adults
Analysis of Medicare data supports findings from younger adults that use of the drug class does not appear to raise fracture risk.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 27, 2021 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Optimal Use of SGLT2 Inhibitors and GLP-1 Agonists Optimal Use of SGLT2 Inhibitors and GLP-1 Agonists
In light of the vast benefits demonstrated by SGLT2 inhibitors and GLP-1 agonists, Dr Matthew Budoff highlights how cardiologists and preventive care physicians can optimize their use in patient care.American College of Cardiology & Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 18, 2021 Category: Consumer Health News Tags: Cardiology Article Source Type: news

Differential Mechanisms in HFrEF and HFpEF in Diabetes Differential Mechanisms in HFrEF and HFpEF in Diabetes
This review explores the pathophysiological mechanisms of heart failure in patients with diabetes, how they differ in patients with HFrEF vs. HFpEF, and the use of SGLT2 inhibitors in these patients.JACC: Heart Failure (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 8, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Which New Drug Class Is Best for Heart Protection in Type 2 Diabetes? Which New Drug Class Is Best for Heart Protection in Type 2 Diabetes?
SGLT2 inhibitors and GLP-1 agonists appear to be equally effective at protecting against stroke and myocardial infarction in patients with type 2 diabetes, but SGLT2 inhibitors are better for heart failure.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 28, 2021 Category: Neurology Tags: Diabetes & Endocrinology News Source Type: news

Dapagliflozin Improves Physical Limitation in HFpEF: PRESERVED-HF Dapagliflozin Improves Physical Limitation in HFpEF: PRESERVED-HF
The SGLT2 inhibitor scored a clear win, showing a significant and clinically meaningful benefit after 12 weeks for the primary endpoint, a measure of symptoms and physical limitations.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 14, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

SGLT2 Inhibitor Use Rising in Diabetic Kidney Disease SGLT2 Inhibitor Use Rising in Diabetic Kidney Disease
' SGLT2 inhibitors are here to stay as a new standard of care for patients with diabetic kidney disease,'said Dr Katherine Tuttle, a nephrologist at Providence Healthcare in Spokane, Washington.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - August 24, 2021 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news

Aug 13 2021 This Week in Cardiology Aug 13 2021 This Week in Cardiology
COVID-19, vaccine-induced myocarditis, Watchman complications, SGLT2 inhibitors, and cardiogenic shock are the topics John Mandrola, MD, discusses in this week ’s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 14, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Dapagliflozin Safe, Protective in Advanced Kidney Disease Dapagliflozin Safe, Protective in Advanced Kidney Disease
' For clinicians, this is now the absolute reassurance that we do not have to stop an SGLT2 inhibitor'in patients with advanced kidney disease, said Dr Chantal Mathieu, about the DAPA-CKD trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 23, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

EMPEROR-Preserved: Positive Top-Line Results for Empagliflozin in HFpEF EMPEROR-Preserved: Positive Top-Line Results for Empagliflozin in HFpEF
The SGLT2 inhibitor met the primary endpoint in adults with heart failure and preserved ejection fraction, with full results to be presented at ESC 2021.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 6, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news

Antidiabetic drug causes double the weight loss of competitor in Type 2 diabetes patients
(University at Buffalo) Patients with Type 2 diabetes who were prescribed SGLT2 inhibitors lost more weight than patients who received GLP-1 receptor agonists, according to a University at Buffalo-led study. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 1, 2021 Category: International Medicine & Public Health Source Type: news

Assays May Guide SGLT2 Inhibitor Use in High CV-Risk Diabetes Assays May Guide SGLT2 Inhibitor Use in High CV-Risk Diabetes
Not all with diabetes at heightened cardiovascular risk may benefit from some of these drugs, so how to choose? And through what mechanisms do SGLT2 inhibitors cut CV risk, anyway?Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 30, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

SGLT2 Inhibitor Better Second-Line Diabetes Pick Than Sulfonylurea When Cost Is Not an Issue SGLT2 Inhibitor Better Second-Line Diabetes Pick Than Sulfonylurea When Cost Is Not an Issue
When metformin fails to sufficiently lower blood glucose levels, it's better to add an SGLT2 inhibitor rather than a sulfonylurea, according to a comparative effectiveness analysis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 30, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

MRAs and SGLT2 Inhibitors: The Best of Both Worlds in HFrEF MRAs and SGLT2 Inhibitors: The Best of Both Worlds in HFrEF
What benefits might the use of these treatments together offer in the management of heart failure with reduced ejection fraction?JACC: Heart Failure (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 22, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Dapagliflozin Misses in COVID-19 but Intriguing Signal of Benefit Dapagliflozin Misses in COVID-19 but Intriguing Signal of Benefit
The SGLT2 inhibitor dapagliflozin was not associated with significant benefit in COVID-19 patients but came close in the DARE-19 trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 18, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Dapagliflozin did not significantly reduce organ failure or death in high-risk patients hospitalized
(American College of Cardiology) Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not significantly reduce the risk of organ failure or death or improve recovery in patients hospitalized with COVID-19 who are at high risk of developing serious complications compared to placebo, according to data presented at the American College of Cardiology's 70th Annual Scientific Session. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 16, 2021 Category: Infectious Diseases Source Type: news

Disparities in SGLT2i Use: Patient Barriers or Physician Bias? Disparities in SGLT2i Use: Patient Barriers or Physician Bias?
A recent study suggests that although the use of SGLT2 inhibitors has increased overall, certain groups are not being prescribed these medications. Dr Akshay Jain looks into possible reasons why.Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 13, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news

May 7 2021 This Week in Cardiology May 7 2021 This Week in Cardiology
COVID-19 and BMI, TAVR vs SAVR, subcutaneous ICD, SGLT2 inhibitors, and physician-Moms are the topics John Mandrola, MD, discusses in this week ’s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 8, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Could Combos Replace Basal-Bolus Insulin in Type 2 Diabetes? Could Combos Replace Basal-Bolus Insulin in Type 2 Diabetes?
Switching patients from multiple daily insulin injections to basal insulin plus either a GLP-1 agonist or an SGLT2 inhibitor produced similar glucose control, with fewer injections and less hypoglycemia.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 6, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Dapagliflozin, Advanced Chronic Kidney Disease, and Mortality Dapagliflozin, Advanced Chronic Kidney Disease, and Mortality
A report on the effects of the SGLT2 inhibitor dapagliflozin on morbidity and mortality in patients with chronic kidney disease suggests these drugs have potential beyond their original use in T2DM.European Heart Journal (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - April 28, 2021 Category: Intensive Care Tags: Nephrology Journal Article Source Type: news

Women, Black, Asian Patients Least Likely to Get SGLT2 Inhibitors Women, Black, Asian Patients Least Likely to Get SGLT2 Inhibitors
"If left unaddressed, these inequities in [SGLT2 Inhibitor] utilization will continue to widen well-documented disparities in cardiovascular and kidney outcomes in the [United States]."Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 23, 2021 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Why Choose Between SGLT2 Inhibitors and GLP1-RA? Why Choose Between SGLT2 Inhibitors and GLP1-RA?
In this commentary, the author urges clinicians to stop wasting time debating whether to use GLP-1RA or an SGLT2 inhibitor in a given patient with T2DM: just pick one--or possibly even both.Circulation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 20, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Gender, Race Affects Access to SGLT2-Inhibitor Therapy for T2DM
MONDAY, April 16, 2021 -- There are racial/ethnic, gender, and socioeconomic disparities apparent in access to sodium-glucose cotransporter 2 (SGLT2) inhibitor treatment for patients with diabetes, according to a study published online April 15 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 19, 2021 Category: Pharmaceuticals Source Type: news

GLP-1 Agonists and SGLT2 Inhibitors in HF Treatment GLP-1 Agonists and SGLT2 Inhibitors in HF Treatment
Although study results have been postive, particularly for SGLT2 inhibitors, questions still need to be answered about how these agents fit into treatment for heart failure.American College of Cardiology & Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 14, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news

SGLT2 Inhibitors in T1D:'People Are Using Them Now'SGLT2 Inhibitors in T1D:'People Are Using Them Now '
Dr Anne Peters talks about what you need to know regarding off-label use of SGLT2 inhibitors in type 1 diabetes.Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 30, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news

Mar 19 2021 This Week in Cardiology Mar 19 2021 This Week in Cardiology
COVID-19, Fish Oil and AF risk, SGLT2 inhibitors and renal outcomes, and TAVR vs SAVR are the topics discussed by John Mandrola, MD, in this week ’s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 19, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Ertugliflozin: Renal Benefits in Additional VERTIS CV Analyses Ertugliflozin: Renal Benefits in Additional VERTIS CV Analyses
The main composite renal endpoint from VERTIS CV didn't show significant benefit from ertugliflozin over placebo, but in additional analyses showed kidney benefits from this SGLT2 inhibitor.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 18, 2021 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

La FDA actualiza las etiquetas de los inhibidores del SGLT2 para la diabetes a fin de incluir advertencias sobre concentraciones de ácido demasiado altas en la sangre e infecciones graves del tracto urinario
[04/12/2015] Una reciente evaluaci ón de seguridad realizada por la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) ha llevado a la adición de advertencias a las etiquetas de una clase específica de medicamentos para la diabetes de tipo 2, llamados inhibidores del cotransportador de sodio-glucosa tipo 2 (SGLT2, por sus siglas en inglés), sobre el riesgo de presentar concentraciones de ácido demasiado elevadas en la sangre e infecciones graves del tracto urinario. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 26, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Further Warning on SGLT2 Inhibitor Use and DKA Risk in COVID-19 Further Warning on SGLT2 Inhibitor Use and DKA Risk in COVID-19
A cluster of cases of diabetic ketoacidosis in which there was no hyperglycemia supports recommendations that SGLT2 inhibitors be discontinued in patients with type 2 diabetes who become ill with COVID-19.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - January 18, 2021 Category: Emergency Medicine Tags: Infectious Diseases News Source Type: news

Jan 15 2021 This Week in Cardiology Jan 15 2021 This Week in Cardiology
COVID, ACE/ARBs, left atrial appendage closure, SGLT2 inhibitors, and a clue in AF mechanisms are the topics discussed by John Mandrola, MD, in this week ’s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 15, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Jan 15 2021 This Week in Cardiology Jan 15 2021 This Week in Cardiology
COVID, ACE/ARBs, left atrial appendage closure, SGLT2 inhibitors, and a clue in AF mechanisms are the topics discussed by John Mandrola, MD, in this week ’s podcast.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 15, 2021 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Biomarker HF Risk Score in Diabetes Seen as SGLT2i Lodestar Biomarker HF Risk Score in Diabetes Seen as SGLT2i Lodestar
Together, 4'easily measured'biomarkers predicted 5-year heart failure risk in patients with diabetes or prediabetes, potentially identifying best candidates for SGLT2 inhibitor therapy, some say.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 14, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Euglycemic DKA ID ’ d in T2DM Patients With COVID - 19
Five cases of euDKA identified in patients with type 2 diabetes using SGLT2 inhibitors who developed SARS - CoV - 2 infection (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - January 5, 2021 Category: Respiratory Medicine Tags: Endocrinology, Family Medicine, Infections, Internal Medicine, Critical Care, Emergency Medicine, Nephrology, Nursing, Pharmacy, Pulmonology, Journal, Source Type: news

Top Cardiology Trials of 2020 in Review Top Cardiology Trials of 2020 in Review
The annual tradition continues as did cardiology research despite a pandemic. Trials on fish oils, statins, SGLT2 inhibitors, and antiplatelets are among the selections of Drs Harrington and Gibson.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 15, 2020 Category: Cardiology Tags: Cardiology Expert Interview Source Type: news

New CREDENCE Data Support SGLT2 Inhibitor Use in Advanced CKD New CREDENCE Data Support SGLT2 Inhibitor Use in Advanced CKD
' We would not recommend initiating treatment with SGLT2 inhibitor in eGFR (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 4, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Canagliflozin Beneficial Even for Advanced Kidney Disease
MONDAY, Nov. 30, 2020 -- Treatment with the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin reduces the rate of kidney disease progression among participants with an estimated glomerular filtration rate (eGRF)
Source: Drugs.com - Pharma News - November 30, 2020 Category: Pharmaceuticals Source Type: news

Regression of LV Hypertrophy With SGLT2 Inhibitors Regression of LV Hypertrophy With SGLT2 Inhibitors
A new study investigates the potential beneficial effects of SGLT2 inhibitors on left ventricular hypertrophy in patients with T2DM. What might be the mechanisms underlying these effects?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 20, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
(American Heart Association) Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.Researchers say the results of this randomized clinical trial provide evidence that SGLT2 inhibitors should be part of the standard of care for people with Type 2 diabetes and chronic kidney disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 17, 2020 Category: International Medicine & Public Health Source Type: news

SCORED and SOLOIST Trials Add to Evidence for Treating Diabetes with SGLT2 Inhibitors
• SCORED trial of patients with diabetes and chronic kidney disease is first trial of an SGLT2 inhibitor to show benefit across the full range of albuminuria • SOLOIST is the first trial to show an SGLT2 inhibitor is safe to start in patients hospit (Source: BWH News)
Source: BWH News - November 16, 2020 Category: Hospital Management Source Type: news

SCORED and SOLOIST trials add to evidence for treating diabetes with SGLT2 inhibitors
(Brigham and Women's Hospital) In these two paired trials, teams of investigators led by Brigham cardiologist Deepak L. Bhatt, MD, MPH, evaluated sotagliflozin, a drug that inhibits SGLT2 and SGLT1. Results of the trials are both published in The New England Journal of Medicine and presented by Bhatt simultaneously at the Late-Breaking Clinical Trial Sessions of the American Heart Association Scientific Sessions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 16, 2020 Category: International Medicine & Public Health Source Type: news

Empagliflozin Favorably Reshaped LVs in HFrEF Patients Empagliflozin Favorably Reshaped LVs in HFrEF Patients
Treatment with the SGLT2 inhibitor empagliflozin led to significant reductions in both left ventricular end systolic and diastolic volumes in two independent randomized studies of patients with heart failure with reduced ejection fraction.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 15, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Adverse Events of High- vs Low-Dose SGLT2 Inhibitors in T2D Adverse Events of High- vs Low-Dose SGLT2 Inhibitors in T2D
SGLT2 inhibitors are commonly used in the treatment of type 2 diabetes, but they are not without side effects. Are the adverse events associated with these agents dose-related?Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 12, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Benefits of SGLT2 Inhibitors Seen Across Patient Subgroups Benefits of SGLT2 Inhibitors Seen Across Patient Subgroups
The benefits of SGLT2 inhibitors are seen in patients with heart failure and in those with chronic kidney disease, data from two pivotal trials, EMPEROR-Reduced and DAPA-CKD, show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 30, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

ESC 2020 Highlights: Drugs Old and New ESC 2020 Highlights: Drugs Old and New
Top trials from the virtual ESC 2020 featured old drugs such as aspirin and colchicine as well as the new SGLT2 inhibitors.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 12, 2020 Category: Cardiology Tags: Cardiology Commentary Source Type: news